19th Jul 2022 12:17
(Alliance News) - Ondine Biomedical Inc on Tuesday said its nasal photodisinfection technology suppressed SARS-CoV-2, the virus that causes Covid-19, in patients who were vaccinated against Covid-19 and had early symptoms of the disease.
The Vancouver, Canada-based life sciences company added the results from northern Spain-based Clinica Universidad de Navarra will be submitted for publication.
"Our goal is to be able to offer a cost-effective Covid-19 treatment and prophylaxis to help our communities deal with SARS-CoV-2 variants and other emerging threats," commented Ondine President Nicolas Loebel.
The trial results come three months after Ondine announced a study proved its Steriwave photodisinfection laser technology was 99.99% effective at inactivating Sars-CoV-2 in mammalian cell culture, reducing viral load to below detection limit within five minutes. The study was published in the Journal of Photochemical & Photobiological Sciences.
Ondine Biomedical shares were 6.8% higher at 42.70 pence each in London on Tuesday.
By Tom Budszus; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Ondine Biomed